I n 1983 and 1984, French and American researchers announced that a virus associated with Acquired Immune Deficiency Syndrome (AIDS) had been identified. This retrovirus, initially labeled human Tcell lvmphotropic virus-III (HTLV-III), lymphadenopathy associated virus (LAV), and AIDS-related virus (ARV), was renamed human immunodeficiency virus (HIV) by international accord in 1986.
Although it is believed that other retroviruses may be associated with AIDS-like illnesses, the identification of HIV as the primary etiologic agent of AIDS in the United States was a landmark event, in part because isolation of the virus was accompanied by the promise of an assay or blood test that would signal the presence of the virus in infected individuals. In the absence of a vaccine or specific treatment for AIDS, it was felt that use of such a test by blood banks would be an important step in helping to eliminate the offending virus from the nation's blood supply.
In May 1985, an AIDS screening assay, commonly called the enzymelinked immunosorbant assay (ELISA) or enzyme immunoassay (EIA) was licensed and released for use in this country. Instead of testing directly for the presence of HIV, this test was designed to detect the presence of anti-HIV antibodies, which are formed in response to infection with HIY. In a very short time, this antibody test was adapted for use by blood and plasma banks as well as by health departments across the country, which then established '~IDS Test Sites" where volunteers could seek a combination of counseling and anonymous or confidential testing for the anti-HIV antibodies.
The philosophy behind these selfreferral centers was that individuals It is essential to understand the concepts of sensitivity and specificity to truly appreciate some of the controversy surrounding testing for the anti-HIV antibody.
found to be infected with HIV could be counseled to change their behavior to reduce the spread of infection. Despite preand post-test counseling, the health care delivery system was, and still is, poorly mobilized to help the antibody positive individual cope with the plethora of emotional and physical health problems associated with HIV infection.
The purpose of this article is to explore the legitimate applications, the inherent limitations, and the nursing ramifications associated with antibody testing for AIDS. To begin, an introduction to laboratory methods used to screen human populations for risk or presence of disease will be presented. Second, characteristics of the retrovirus family, and HIV in particular, as well as the body's response to HIV infection, will be discussed. Third, common antibody tests used for AIDS screening will be explained. Finally, specific applications will be made to clinical practice, so that the occupational health nurse specialist can make informed and knowledgeable decisions relative to antibody testing whenever questions anse.
LABORATORY SCREENING
METHODS Since occupational health nurses are frequently involved in screening members of the workforce for risk of disease, most are quite familiar with laboratory tests used for this purpose. For example, it might be necessary to ascertain which workers have dangerously high levels of triglycerides, sugar, or toxic substances in blood or body fluids. Tests that accurately separate high risk or diseased individuals from low risk or healthy ones are employed. When a test or lab procedure is accurate in this way, it is said to be efficacious, in which case it has high sensitivity and specificity.
Sensitivity refers to the ability of a test to identify all positive cases, whereas specificity is the ability of a test to exclude or accurately identify all negative cases. For example, an efficacious test for anti-HIV antibody would correctly identify all individuals who are positive for the antibody, while correctly excluding all those who are negative.
To carry the example further, it is easy to see why test sensitivity and specificity are so crucial. If the anti-HIV antibody test had poor sensitivity, it would fail to correctly identify infected individuals, who would then have no reason to modify sexual behavior or blood and organ donation. Worse yet, a false negative test on donated blood would allow the contaminated blood to be released for use. Conversely HIV invades T lymphocytes, where it grows, multiplies, and eventually destroys or weakens the immune system, rendering the client vulnerable to opportunistic infections. 
THE RETROVIRUSES
The human immunodeficiency virus is a member of the group of RNA-containing viruses called retroviruses, so named because of a unique biochemical reaction that is part of their reproductive cycle. Whereas most organisms are capable of using DNA as a pattern to produce complimentary molecules of RNA, only the retroviruses can induce the reverse reaction, the production of DNA, using RNA as the pattern. This is accomplished by an enzyme, reverse transcriptase, found only in this group of viruses.
The basic structure of the retrovirus is similar to that of many other viruses. It consists of a core containing genetic material enclosed in a protein sheath. The core is surrounded by an envelope of lipid, in which combinations of protein and carbohydrates called glycoproteins are anchored. Persons infected with HIV may produce antibodies against specific core protein antigens and envelope glycoprotein antigens.
One envelope antigen plays a major role in allowing the virus to infect certain white blood cells in humans. Unfortunately, this molecule is positive . It is easy, therefore, to understand the grave consequences of a false positive anti-HIV antibody test.
It is essential to understand the concepts of sensitivity and specificity to truly appreciate some of the controversy surrounding testing for anti-HIV antibody. Like virtually every other screening test, including a chest x-ray or complete blood count (CBC), these antibody tests have a recognized error factor. Sometimes results are false positive (ie, the test reads positive in a person who is not infected and, therefore, has not formed antibodies), and they can also be false negative (ie, the test reads negative in a person who is infected and has formed antibodies). The likelihood of false positives and negatives will be discussed after a brief review of the pathophysiology of retroviruses in general, and HIV in particular. Medicine, 1986; Monzori, 1987; "One AIDS," 1987. "'STLV = simian T-celllymphotropic virus known to be highly variable in structure, and this variability complicates the task of producing a vaccine that will prevent infection.
Institute of
The retrovirus family includes at least two subfamilies. One subfamily contains oncogenic viruses, such as those which cause leukemias and lymphomas in cats, mice, and cows. An example of these oncogenic viruses familiar to cat owners is feline leukemia virus. A second subfamily of the retroviruses is known as the lentiviruses (Ienti-= slow) because of the long latent period that usually exists between infection and development of clinical symptoms. Some Ientiviruses cause encephalitis and other conditions in horses, sheep, and goats. HIV is a member of the Ientivirus family.
Although retroviruses that infect animals have been known for years, the first retrovirus to affect humans was identified in 1978 from a man with T-cell leukemia. This virus was initially named human T-cell Iymphotropic virus (HTLV) and later, HTLV-I (Gallo, 1986) .
Several other retroviruses with the ability to cause leukemia and/or immunodeficiency in humans have been isolated. These and certain simian (monkey) viruses are listed in Figure 1. It is generally believed that strains of simian viruses, at some point in time, acquired the ability to infect humans and were precursors to HTLV-I and HIV (Institute ofMedicine, 1986).
HIV Infection and Anti-HIV Antibody Production
Once HIV particles gain access to the human body, they typically bind to specialized white blood cells called T4, or helper T-cells. As a consequence of this binding, the virus particle is taken into the cell where its RNA is used to make DNA, which becomes a permanent part of the genetic structure of the cell.
In response to invasion by HIY, the body's immune system produces anti-HIV antibodies. These antibodies appear to remove detectable HIV antigen from the blood. However, unlike antibodies formed in response to many other infectious disease agents, anti-HIV antibodies are unable to neutralize or destroy the virus and thus limit the infection (Institute of Medicine, 1986). In essence then, antibodies are formed in response to HIV infection, but the antibodies are not protective.
In general, antibody titers of people in the later stages of AIDS are lower than those of newly diagnosed persons (Sarngadharan, 1984) . This could be explained by the fact that the pathogenesis of AIDS involves a reduction in T4 lymphocytes, cells which normally facilitate antibody production by B-Iymphocytes. In other words, as the immune system becomes more compromised, it loses its ability to manufacture even the non protective anti-HIV antibodies.
Infection and initial production of anti-HIV antibodies, which is sometimes accompanied by a mild influenza-like illness, is followed by a latent period in which the individual typically remains antibody positive but asymptomatic. This asymptomatic state may last weeks, months, or years, but the average incubation period for full-blown AIDS is approximately seven years (Centers For Disease Control, 1987) .
The stimulus that ends the latent period by inducing the synthesis of new HIV particles has not been definitively identified, but it may be associated with reinfection with HIV or exposure to other infectious agents. It is known that when synthesis of new HIV occurs, virus particles are assembled in the white blood cell cytoplasm and escape through the cell membrane, often killing the cell in the process. Loss of these T-Iymphocytes leads to the demise of the immune system, allowing the development of the rare cancers or opportunistic infections producing the signs and symptoms of AIDS.
Adaptedfrom ''AIDSand AIDS-RelatedConditions: ScreeningforPopulations at Risk" byG.S. Carr and G. Gee. TheNursePractitioner: TheAmerican Journalof Primary Health Care1986; 11(10):44. "'ARC = AIDS-Related Complex
FIGURE 2 Facts about Antibody Tests for AIDS
The "AIDS antibody" is a protein naturally produced in the body in response to the AIDS virus. The test is not completely accurate. It will NOT tell you whether you have AIDS or ARC* or if you will develop AIDS or ARC in the future. It will NOT tell you if you are immune to AIDS.
A Positive Test Result DOES Mean:
• Antibodies to the AIDS virus are present in your blood. • You have been infected with the AIDS virus and your body has produced antibodies. • You probably have active virus in your body and should assume that you are capable of passing the virus to others.
A Positive Test DOES NOT Mean:
• You necessarily have AIDS or ARC. • You will necessarily get AIDS or ARC in the future. • You are immune to AIDS or ARC.
A Negative Test DOES Mean:
• Antibodies to the virus are not present in your blood at this time. Two possible reasons for this are: • You have not been infected with the virus, OR • You have been infected with the virus, but have not yet produced antibodies (which takes from two weeks to six months, or even longer).
A Negative Test DOES NOT Mean:
• You have nothing to worry about (you may contact the virus and become infected at a later date). • You are immune to the virus. • You have not been infected with the virus (you may have been infected and have not yet produced antibodies).
TESTS USED TO DETECT
ANTI-HIV ANTIBODIES The fact that a person has been infected by HIV can be detected in a number of ways. Among these are viral culture and testing for viral antigens or antiviral antibodies. Viral culture and antigen testing are largely limited to research or highly specialized settings because both are complex procedures requiring special equipment and specially trained personnel.
Therefore, state-of-the-art screening for HIV relies upon detection of anti-HIV antibodies, which are usually formed within two weeks to several months of infection, and which generally persist to some degree throughout the lifetime of an infected individual. As noted earlier, quantifiable amounts of antibody are generally higher in newly infected individuals or during the latent period before the immune system becomes overwhelmed.
Noteworthy are reports that some people require 18 months or longer before producing antibodies that are detectable on an ELISA screening test (Ranki, 1987) and that some antibody positive individuals have subsequently converted to negative (Burger, 1985; "Five Antibody," 1987) . These instances remain largely unexplained, but transient antibody production may relate to the fact that as infection progresses, the immune system fails to produce even nonprotective antibodies. If an infected individual is tested before producing a detectable level of antibodies or if the antibody level has fallen too low to be detected, the screening test result will be negative. Although this result is technically a true negative (a minimal amount of antibodies are present in the blood), it would lead to the false conclusion that the person is not infected with HIY.
The ELISA and Western Blot
The previously mentioned immunologic assay called the ELISA, which detects anti-HIV antibodies in the blood, has been widely used since it became available in 1985. Positive ELISA test results are rou-tinely confirmed by another assay, the Western Blot (WB).
To obtain a specimen for ELISA and WB Testing, 5cc of venous blood is obtained and centrifuged. Only the plasma or serum is used, and the blood sample can be taken at any time, since results are not known to be affected by dietary intake or other chemical characteristics of the blood.
The ELISA is run first and is a general measure of anti-HlV antibodies in the blood. No attempt is made in this assay to separate or identify antibodies to specific HIV antigens. Advantages of the ELISA are that it is relatively inexpensive (usu-ally less than $10.00), it is comparatively easy to perform, and its sensitivity and specificity have improved since 1985.
The ELISA, when used alone, is associated with an unacceptably high level of false positive results. One reason for a false positive result is that the antigen test solution could have been contaminated by antigens from the human cells in which the virus was grown. A client's serum may react with these antigens. This problem will be controlled to a certain extent when "second generation" ELISAs become available. These tests, which are currently being developed, some laboratories choose the unlicensed kits because they are less expensive to purchase.
AIDS Tests
use more purified HIV antigens.
A more important reason for an unacceptably high level of false positive ELISA results is that all screening tests are known to be less accurate when there is a lower percentage of infected individuals in the population tested than when the percentage is high. This can be explained using the example of fishing. When fishing, one is more likely to reel in a piece of debris (a false positive result) than a fish (a true positive result) if there are few fish in the pond. Thus, one ELISA alone will produce too many false positive results when it is used in a population with a relatively low incidence of HIV infection, such as blood donors in rural areas or applicants for marriage licenses.
The problem offalse positive reactions with the ELISA can be partially controlled by performing two different ELISA tests on the same serum sample. For this reason, it is generally recommended that two ELISA assays be performed. If either ELISA is reactive, a WB (or another very specific test such as an immunofluorescence assay) is performed. When the WB is reactive, the individual is said to be positive for anti-HIV antibodies and is assumed to be HIV infected. However, if the WB is nonreactive, the reactive ELISA is called a false positive, and the person is said to be negative for anti-HlV antibodies and is assumed noninfected. Noteworthy is the fact that WB test results may also be reported as indeterminate, which then requires additional testing on the original blood sample or obtaining additional samples for retesting (Centers for Disease Control, 1988) .
Unlike the ELISA, the WB assay can detect antibodies to particular or specific HIV antigens, and thus is regarded as highly specific. It is also more sensitive than the ELISA (Ranki, 1987) . That is, it has a greater ability to detect true positives than does the ELISA. However, the WB laboratory technique is more laborintensive and more expensive ($45.00 or more).
Because of the particular strengths
The issues of who should be tested, when, and where are complex and sensitive ones which require effective risk appraisal, communication, and teaching skills.
and weaknesses of each test, it is generally recommended that screening for HIV antibodies involve two ELISA assays ideally with each ELISA being performed with a different test kit even though the same serum is used. When either or both of the ELISAs are reactive, the confirmatory WB is performed. Only when the WB is reactive is there serologic evidence of HIV infection as indicated by the presence of anti-HIV antibodies (Centers for Disease Control, 1988) . Some basic factors about antibody tests for AIDS are displayed in Figure  2 . Even though a positive antibody test (as confirmed by WB) does mean that the individual is, in all likelihood, infected with the AIDS virus, it does not lend any prognostic information. Although it is currently believed that most infected people will develop some kind of AIDSrelated illness at some point in time (Centers for Disease Control, 1987) , it is impossible to predict which antibody positive individuals will develop AIDS or AIDS-like illness and when the illness will appear.
Finally, it should be noted that laboratories that use FDA licensed ELISA or WB kits generally experience greater sensitivity than those that use unlicensed kits. However,
ISSUES FOR CLINICAL PRACTICE

Who Should Be Tested?
Even though antibody testing is probably inappropriate in the work setting (except in some health care settings) because of confidentiality issues, nurses are often consulted by a variety of lay persons and health care professionals for advice concerning whether or not to seek out antibody testing. The issues of who should be tested, when, and where, are complex and sensitive ones requiring effective risk appraisal, communication, and teaching skills.
To begin, nurses should be aware that some mechanisms for routine HIV screening of certain groups are already in place. For example, all reputable blood banks and plasma centers screen donors for anti-HIV antibodies. When the donor is positive on the ELISA test, the blood or plasma is discarded. Generally donors are not notified that they have a positive test until a confirming WB is performed.
Other routine screening programs currently exist for immigrants, federal prison populations, civilian applicants for military service, and members of the armed forces. Additionally, different states have enacted laws governing the circumstances under which citizens either may be required or recommended to submit to an anonymous or confidential antibody screening test for AIDS. For example, clients participating in sexually transmitted disease clinics or family planning or prenatal clinics in Alabama are encouraged to submit to testing. A signed consent form is obtained before testing and appropriate counseling is done. Because laws vary from one state to another, and because new AIDS-related legislation is likely to be enacted at each legislative session, the occupational health nurse must make a conscientious effort to stay abreast of pertinent state laws that govern the individual work setting.
FIGURE 3
Benefits and Risks of HIV-Antibody Testing BENEFITS For The Individual: • Decreases anxiety in a worried, non-infected person with a low-risk lifestyle.
• Confirms the diagnosis of AIDS in a person with other manifestations of the disease. • Provides information for making decisions regarding pregnancy or breastfeeding. • Testing of a high-risk infant provides information for making decisions regarding immunization with a live virus vaccine, which would be inadvisable for an immunosuppressed infant.
• Early detection of HIV infection may allow a change in lifestyle that may prevent other infections.
For Others: • Prevents transmission of HIV via blood or blood products. • Prevents transmission of HIV via artificial insemination or organ transplantation.
• Knowledge of HIV infection may motivate an individual to modify high-risk behaviors, thus protecting others.
• Contributes to knowledge about the natural history of the disease, its transmission, and its prevalence in different segments of the population.
• Use of test data by researchers contributes to the development of mechanisms for prevention or control of AIDS. Goldblum, 1987. RISKS For The Individual: • Harmful psychological reactions to a positive test result, including depression, anxiety, suicide, and desire for revenge. • Stress on relationships with family members, significant others, or friends. • Worry about the development of AIDS, leading to excess anxiety over minor symptoms, which may not be related to HIV infection. • Self-imposed withdrawal from usual social contacts.
• Ostracism by others who are misinformed about the modes of transmission of the virus. • Discrimination in employment, insurance, and housing.
• False sense of security from a negative test result, leading to a sense of invincibility and the continuation of high-risk behaviors.
• Sense of survivor guilt in non-infected persons.
Risks Or Problems:
• The probability of anti-HIV antibody testing at hospitals and clinics may prevent people with other health problems from seeking health care at these sites.
• Testing must be repeated at intervals on a seronegative person if high-risk behavior continues. • If tests are done anonymously, there is no dependable mechanism to notify either individuals or their partner(s) of a positive result.
Risk Appraisal and Counseling
Basically, individuals fall into one of three risk categories relative to exposure to or infection with HIV: high risk, low risk, and the worried well. Examples of high risk group members are: • Hemophiliacs who may have received HIV contaminated lots of intravenous clotting factor before 1985 (risk is higher among hemophilia A clients). • Homosexual or bisexual men (especially those who have multiple sexual partners and/or engage in high risk activities such as anal intercourse). • IV drug users (especially those who share needles). • Blood transfusion recipients, if the transfusion occurred prior to May, 1985. • Prostitutes. • Sexual partners of known HIV positive individuals or those in the high risk categories listed above. All members of high risk groups should be encouraged to be antibody tested so that, if positive, they can be advised to avoid pregnancy, practice barrier sex (using condoms), and not donate blood, semen, or body organs. Antibody test results should be given in a private one-to-one session and accompanying counseling should include advice on maximizing health potential and strictly avoiding possible re-exposure to HIY.
It is more difficult to decide when low risk or worried well individuals should be advised to be antibody tested. Low risk or worried well individuals include people who may not have been mutually monogamous over the past several years or those support systems that they could call upon. These can be reviewed during post-test counseling. Options for medical and psychological help can also be discussed at this time.
Most states offer screening programs that are either free or have a minimal charge and guarantee either anonymity or confidentiality to clients. From the standpoint of confidentiality, people who consider antibody testing should know that different test sites handle reporting of test results differently. Clients should be told to ask who would have access to test results and how confidentiality is assured. For example, in most instances test results should be given verbally, in person, instead of mailed or telephoned, both for the sake of confidentiality and also to provide an opportunity for appropriate education and counseling regardless .of the test results. who feel that they may have had blood or sexual contact with HIV infected persons. Also included in this group are health care professionals who fear past occupational exposure. When the nurse is consulted by a worried well individual, it is helpful to assist the client in assessing risks and benefits of antibody testing as outlined in Figure 3 .
Being antibody tested for HIV infection is a different experience from virtually any other screening procedure. First, if strict confidentiality is not maintained, the person in question can suffer innumerable personal consequences such as loss of job and/or insurance and family upheaval. Second, ELISA and WB test results typically take several days to be reported, and during this time the client must deal with a number of psychological issues including the possibility that test results may be positive. Third, and most unfortunate, there may be a social stigma attached to obtaining such testing. For example, clients in small or close-knit communities are reluctant to seek testing in a centrally located health department setting where "everyone knows everyone."
The bottom line for advising people on antibody testing is to make sure that they are made aware of the potential risks and benefits so that they will be equipped to make their own decisions. Goldblum and Seymour (1987) , of the AIDS Health Project at the University of California at San Francisco, recommend that the counseling process have three components. The first is presentation of accurate information concerning the antibody test and its interpretation. Figure 2 illustrates some of the facts that need to be covered. The second element is a mechanism that allows the client to make a rational decision on whether or not to be tested. A benefit-risk analysis based on those items mentioned in Figure 3 that pertain to the individual's own situation is one way in which this may be accomplished. Finally, if persons decide to have the test performed, they need to explore "an action plan that will maximize benefits and minimize risk" (Goldblum, 1987) . For instance, the clients might consider how they would react to a positive test result and identify
SUMMARY
The anti-HIV antibody tests have been available for three years in mid-1988. Their accuracy has been improved and their general usage expanded to include more diverse segments of the population. Use of these antibody tests has been and will continue to be an emotionally charged issue because seropositivity connotes life-long infection and uncertain prognosis.
From the time of initial release of these antibody tests, federal agencies have consistently underscored the element of confidentiality of test results and the importance of preand post-test counseling regardless of test results. Yet, as usage of the tests is extended to insurance underwriters, private industry, federal agencies, and private practitioners, it is difficult to predict whether confidentiality rights will be upheld and what the quantity and quality of preand post-test counseling will be.
Health care professionals, especially nurses, are often consulted by clients and others because they are perceived to be knowledgeable about issues such as AIDS-related illnesses and AIDS-test counseling. We must respond to this challenge as an oppor-tuniry to disseminate accurate information and to facilitate decision making processes relative to anti-HlV antibody testing.
